Reuters Market Eye - Ranbaxy Laboratories (RANB.NS) gains 0.2 percent to 481 rupees after Nomura upgrades the stock to "buy" from "reduce" and raises its target price to 543 rupees from 321 rupees on the back of its takeover by Sun Pharmaceutical Industries (SUN.NS).

Although Nomura says Ranbaxy shares look expensive on valuation, it notes the stock should now move in tandem with Sun Pharma, hence the steep increase in its target price.

Ranbaxy shares are trading well above the Sun offer that valued the takeover target at 457 rupees apiece.

Trending On Reuters

REUTERS EXCLUSIVE

India's main public health programmes, aimed at millions of rural poor, have been in disarray for months because the government changed the way that over $1.3 billion in funds were distributed, according to data and letters seen by Reuters. Full Article | Graphic: India's health funding